Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.

You may also be interested in...



FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs

Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs

FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs

Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs

FDA Rules On Treatment INDs May Embolden More Patients To Ask For Trial Drugs

Agency expects individual patient INDs to rise by 50 percent as a result of new regs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel